Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 02, 2020 07:30 ET | Source: VIVUS, Inc.

VIVUS Completes Enrollment in Phase 4 Safety and Efficacy Study of Qsymia® in Adolescents

-Post-marketing study designed to evaluate Qsymia as an approach to weight management in a growing patient population with significant unmet medical need- CAMPBELL, Calif., March 02, 2020 (GLOBE...
February 19, 2020 07:30 ET | Source: VIVUS, Inc.

VIVUS Announces Commercial Launch of Qsymia® in the Republic of Korea Establishing New Royalty Revenue Stream

- VIVUS to Receive Milestone Payment from Alvogen; Significant Worldwide Growth Potential for Qsymia - CAMPBELL, Calif., Feb. 19, 2020 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq:VVUS) (the...
February 18, 2020 07:30 ET | Source: VIVUS, Inc.

VIVUS to Host Fourth Quarter Business Update and Financial Results Conference Call on Tuesday, March 3, 2020

CAMPBELL, Calif., Feb. 18, 2020 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq: VVUS) today announced that it will report financial results and provide a business update for the fourth quarter of 2019...
February 05, 2020 07:30 ET | Source: VIVUS, Inc.

VIVUS Receives U.S. Food and Drug Administration Approval for Improved Formulation of PANCREAZE® with a 36-Month Shelf Life

CAMPBELL, Calif., Feb. 05, 2020 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq: VVUS) (“VIVUS”), a biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved...
January 07, 2020 07:30 ET | Source: VIVUS, Inc.

New Data Further Demonstrate Effectiveness of VIVUS’ Qsymia as a Weight Management Tool

-Data published in Journal of General Internal Medicine show that patients using Qsymia and other weight loss tools, lost at least 5% of body weight loss compared with those not using Qsymia- ...
January 02, 2020 07:30 ET | Source: VIVUS, Inc.

VIVUS to Present at Biotech Showcase on January 13, 2020

CAMPBELL, Calif., Jan. 02, 2020 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq: VVUS) (the “Company”), a biopharmaceutical company, today announced that John Amos, Chief Executive Officer, will present at...
December 31, 2019 07:30 ET | Source: VIVUS, Inc.

VIVUS Adopts Stockholder Rights Plan

CAMPBELL, Calif., Dec. 31, 2019 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq: VVUS) (the “Company”), a biopharmaceutical company, today announced that on December 30, 2019 its board of directors adopted...
December 18, 2019 07:30 ET | Source: VIVUS, Inc.

VIVUS Announces New Data Supporting the Safety and Efficacy of Qsymia® in Adolescents with Obesity

-Data published in Diabetes, Obesity and Metabolism demonstrate that Qsymia provides statistically significant weight loss compared with placebo over an 8 week period, provide basis for ongoing 56...
November 25, 2019 07:30 ET | Source: VIVUS, Inc.

VIVUS to Present at Piper Jaffray 31st Annual Healthcare Conference on December 3, 2019

CAMPBELL, Calif., Nov. 25, 2019 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq: VVUS) (the “Company”), a biopharmaceutical company, today announced that John Amos, Chief Executive Officer at VIVUS, will...
November 20, 2019 07:30 ET | Source: VIVUS, Inc.

New Clinical Data Demonstrate VIVUS’ Qsymia® is Effective at Reducing Binge Eating in Patients with Binge-Eating Disorder or Bulimia Nervosa

-Data published in International Journal of Eating Disorders show patients in the Qsymia group had 75% decrease in binge day frequency compared with 19% for placebo- CAMPBELL, Calif., Nov. 20,...